Raymond James Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to $150
Raymond James analyst Danielle Brill maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and lowers the price target from $163 to $150.
Neurocrine Biosciences: Q3 Earnings Insights
Neurocrine Biosciences (NASDAQ:NBIX) reported its Q3 earnings results on Monday, November 1, 2021 at 04:01 PM.
Here's what investors need to know about the announcement.
Neurocrine Biosciences’s Return On Capital Employed Overview
According to Benzinga Pro, during Q2, Neurocrine Biosciences (NASDAQ:NBIX) earned $62.80 million, a 99.37% increase from the preceding quarter. Neurocrine Biosciences also posted a total of $288.90 million in sales, a 22.1% increase since Q1.
Earnings Scheduled For November 1, 2021
Companies Reporting Before The Bell
• ANI Pharmaceuticals (NASDAQ:ANIP) is expected to report earnings for its third quarter.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Morgan Stanley Downgrades Neurocrine Biosciences to Equal-Weight, Announces $112 Price Target
Morgan Stanley analyst Jeffrey Hung downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Overweight to Equal-Weight and announces $112 price target.
Neurocrine Biosciences To Present New INGREZZA (valbenazine) And ONGENTYS (opicapone) Data At MDS Virtual Congress 2021
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that it will present new data from its movement disorder treatments for tardive dyskinesia (TD) and Parkinson's disease at the International Parkinson
Looking into Neurocrine Biosciences’s Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, Neurocrine Biosciences (NASDAQ:NBIX) earned $62.80 million, a 99.37% increase from the preceding quarter.
The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 12)